Supernus Pharmaceuticals Inc (SUPN) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Supernus Pharmaceuticals inc   (NASDAQ: SUPN)

Supernus Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Supernus Pharmaceuticals Inc in the third quarter 2026?
Supernus Pharmaceuticals Inc recorded a cumulative net loss of $-44 million during 12 months ending in the third quarter 2026, resulting in a negative return on equity (ROE) of -4.14%.

Within the Major Pharmaceutical Preparations industry 79 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 2401 to 2461.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change 1.22 % -3.07 % 4.47 % 2.51 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -44 -110 -29 -39 -19
Return On Equity (TTM) -4.14 % -10.42 % -2.73 % -3.67 % -1.83 %
SUPN's Total Ranking # 2461 # 2401 # 1711 # 2203 #
Equity (TTM) in Millions 1,062 1,031 1,077 1,062 1,050
Seq. Equity Change 3.03 % -4.23 % 1.42 % 1.15 % -1.34 %
Seq. Net Income Change - - - - -

Back to SUPN Management Effectiveness >> SUPN's 5 Years Annual ROE >> Compare SUPN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 80
Sector # 239
Overall # 2461

Return On Equity Statistics
High Average Low
71.49 %
-9.89 %
-282.81 %
(Sep 30 2016)   (Mar 31 2014)





SUPN Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 1,062 1,036 886 816 745
Y / Y Equity Change 2.51 % 16.87 % 8.62 % 9.53 % 25.1 %
Net Income in Millions -39 74 61 53 127
Y / Y Net Income Change - 21.67 % 13.64 % -57.92 % 12.29 %
Return On Equity -3.63 % 7.13 % 6.85 % 6.55 % 17.04 %

Back to SUPN Management Effectiveness >> SUPN's 5 Years Annual ROE >> Compare SUPN ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
SUPN's' Return on Equity at Yahoo Finance
SUPN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for SUPN's Competitors
Subscribers only: Roe for Supernus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for SUPN's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE

Date modified: 2026-10-30T17:00:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.